Breaking Down Yangmei Chemical Co.,Ltd Financial Health: Key Insights for Investors

Investors scrutinizing Yangmei Chemical Co., Ltd. will find a mixed picture: first-half 2025 revenue of 5.13 billion yuan (down 0.63% year‑on‑year) after a full‑year 2024 revenue of 10.89 billion yuan (down 20.01%), revenue per employee of 1.93 million yuan across 5,434 staff, and a market capitalization of 7.15 billion yuan (Oct 15, 2025); profitability remains a concern with a H1 2025 net loss attributable to shareholders of about 229 million yuan (a 20.18% improvement), negative EPS of -0.0962 yuan/share and TTM net income of -657.46 million yuan, while gross profit slid to 339.54 million yuan in H1 2025 from 516.76 million yuan a year earlier; leverage and liquidity metrics underline material risk - total debt of 7.65 billion yuan, debt‑to‑equity of 1.98, net cash position of -5.08 billion yuan, enterprise value of 12.68 billion yuan versus market cap 7.15 billion yuan, EV/EBITDA of -33.28, interest coverage of -1.70, current ratio 0.73, quick ratio 0.47 and cash of 2.57 billion yuan - yet valuation and outlook offer potential entry points with a P/S of 0.69, P/B of 1.79, 52‑week price gain of 4.66%, beta 0.73, EPS TTM -0.28, forecasts of earnings growth ~111.1% p.a. and revenue growth ~2.9% p.a., a projected EPS CAGR of 110.3% and a 3‑year ROE of 1.2%, and a 2025 financing limit not exceeding 10.26 billion yuan-keep reading for a chapter‑by‑chapter breakdown of these figures and what they mean for risk and opportunity.

Yangmei Chemical Co.,Ltd (600691.SS) - Revenue Analysis

• Total revenue H1 2025: 5.13 billion yuan (down 0.63% vs H1 2024).
• Full-year revenue 2024: 10.89 billion yuan (down 20.01% vs 2023).
• Employees (as of 2024-12-31): 5,434.
• Revenue per employee (2024 basis): 1.93 million yuan.
• Market capitalization (2025-10-15): 7.15 billion yuan.

• The steep 20.01% decline in 2024 revenue signals material demand or pricing pressure across core products.
• H1 2025 shows stabilization but not recovery (only -0.63% YoY), suggesting either conservative inventory/sales management or continued weak end-market demand.
• Revenue per employee at 1.93 million yuan implies reduced workforce productivity relative to historical levels or industry peers; potential inefficiency if headcount hasn't been adjusted to lower sales.
• Market cap of 7.15 billion yuan (Oct 15, 2025) compared with trailing revenue (~10.89 billion in 2024) implies an enterprise valuation roughly in the range of 0.66x revenue (market cap / FY2024 revenue), a useful reference for relative valuation but requiring debt/cash adjustments for EV comparisons.

Yangmei Chemical Co.,Ltd (600691.SS) - Profitability Metrics

• Net loss attributable to shareholders (H1 2025): ≈‑229 million yuan - improvement of 20.18% year‑over‑year.
• Basic earnings per share (H1 2025): ‑0.0962 yuan/share (negative).
• Trailing twelve months (TTM) operating income: ‑465.70 million yuan (operational loss on a TTM basis).
• TTM net income: ‑657.46 million yuan (continued overall loss for the year‑ended period).
• Gross profit (H1 2025): 339.54 million yuan, down from 516.76 million yuan in H1 2024 - declining gross margin trend.
• Profit margin: negative (company failing to convert revenue into net profit over recent periods).
• ROA / ROE: not reported explicitly for the period; absence of positive ROA/ROE figures aligns with negative profitability metrics.

• Gross‑margin compression: gross profit fell ~34.3% YoY (339.54M vs 516.76M), signaling margin pressure from either lower selling prices, higher input costs, or a shift in sales mix.
• Improving headline loss but persistent unprofitability: the 20.18% improvement in H1 loss reduces immediate downside but EPS remains negative and TTM figures show ongoing losses.
• Balance of operating vs non‑operating impacts: negative operating income (TTM: ‑465.70M) indicates core business weakness rather than one‑off charges alone.
• Missing positive ROA/ROE: absence of explicit ROA/ROE metrics and negative net income suggest poor returns on equity and assets; investors should expect depressed efficiency ratios until profitability reverses.

Yangmei Chemical Co.,Ltd (600691.SS) - Debt vs. Equity Structure

Yangmei Chemical's capital structure shows a clear tilt toward debt financing, with leverage and coverage metrics signaling material stress on operating cash flows and solvency. Key headline figures are summarized below and discussed for investor implications.

• Leverage profile: Debt-to-equity of 1.98 indicates the company relies heavily on borrowed funds versus shareholder capital; equity buffers are thin relative to obligations.
• Coverage stress: Interest coverage at -1.70 and debt-to-EBITDA of 30.95 point to operating earnings that are either negative or too small to service interest and principal without refinancing or asset sales.

• Balance-sheet snapshot: Total debt of 7.65 billion CNY combined with net cash of -5.08 billion CNY implies material net indebtedness-net liabilities exceed cash by >5 billion CNY.
• Valuation vs. capital structure: EV (12.68B) > Market Cap (7.15B) by ~5.53B, reflecting debt load embedded in enterprise value and potential market skepticism; alternatively, could signal undervaluation if future cash flows recover.

Investor-focused risks and operational implications:

• Refinancing risk: With leverage this high and negative interest coverage, the company may face difficulty rolling short-term maturities or obtaining new debt without dilutive equity or higher rates.
• Liquidity pressure: Negative net cash (-5.08B) constrains flexibility for capex, working capital, or margin cushions during downturns.
• Potential dilution: The stated 2025 financing ceiling (≤10.26B) signals intent/need to raise material capital; equity raises would dilute current holders, while debt raises deepen leverage.
• Bondholder/covenant risk: High debt-to-EBITDA increases probability of covenant breaches if earnings remain weak, possibly triggering restructuring or accelerated repayments.

What to monitor (near-term triggers):

• Quarterly EBITDA and operating cash flow trends vs. interest and principal schedules.
• Announcements on the structure and timing of any 2025 financing (debt vs. equity, pricing, covenants).
• Asset sales, government or parent support, or strategic partnerships that could materially reduce net debt.
• Market reaction to earnings and guidance, which will influence market cap and EV spreads.

For investors wanting deeper context on shareholder composition and trading-side dynamics, see: Exploring Yangmei Chemical Co.,Ltd Investor Profile: Who's Buying and Why?

Yangmei Chemical Co.,Ltd (600691.SS) - Liquidity and Solvency

• Current ratio: 0.73 - below 1.0, indicating current liabilities exceed current assets and potential difficulty meeting short-term obligations.
• Quick ratio: 0.47 - indicates limited immediate liquidity without relying on inventory liquidation.
• Net cash position: -5.08 billion yuan - negative net cash signals dependence on external financing or asset sales to cover debt.
• Cash & cash equivalents: 2.57 billion yuan vs. Total debt: 7.65 billion yuan - cash covers only ~33.6% of total debt.
• TTM operating income: -465.70 million yuan - continued operating losses erode working capital and increase refinancing risk.
• TTM net income: -657.46 million yuan - persistent net losses that reduce equity cushions for creditors.

• Refinancing risk: With negative net cash and sizable debt, maturity profile and access to credit markets are critical.
• Working capital strain: Low current and quick ratios raise risk of supplier/payment disruptions absent additional liquidity.
• Operational recovery dependency: Return to positive operating income is necessary to improve solvency metrics organically.
• Investor considerations: Monitor covenant headroom, upcoming debt maturities, and management plans for deleveraging or capital raises.

Yangmei Chemical Co.,Ltd (600691.SS) Valuation Analysis

• Market-cap vs. EV: EV (¥12.68b) materially exceeds market cap (¥7.15b), reflecting net debt or minority/other obligations priced into enterprise value.
• Valuation multiples: P/S of 0.69 implies revenue is large relative to market value, a potential sign of undervaluation versus peers if margins/revenue quality are sustainable.
• P/B at 1.79 indicates the stock trades at a premium to book - investors pay for intangible value, earnings potential, or higher ROE expectations despite negative EPS.
• EPS of -0.28 shows the company is currently loss-making; reconcile negative earnings with low P/S to assess operational versus structural issues.
• Low beta (0.73) and modest 52-week +4.66% return point to lower volatility and mild positive market sentiment despite losses.

Yangmei Chemical Co.,Ltd (600691.SS) - Risk Factors

• EV/EBITDA: -33.28 - negative multiple signaling enterprise value exceeds operating profitability in the trailing period and indicating potential solvency concerns.
• Debt-to-Equity: 1.98 - nearly 2:1 leverage, showing high reliance on debt financing relative to equity.
• Interest Coverage Ratio: -1.70 - EBIT insufficient to cover interest expenses; the company is generating negative coverage.
• Net Cash Position: -5.08 billion CNY - a significant net debt/liquidity shortfall.
• Operating Income (TTM): -465.70 million CNY - ongoing operating losses.
• Net Income (TTM): -657.46 million CNY - continued bottom-line losses.

• Refinancing and covenant risk: High leverage and negative interest coverage raise the probability of covenant breaches and costly refinancing or equity raises.
• Liquidity squeeze: A -5.08 billion CNY net cash position limits the firm's ability to absorb shocks or invest in turnaround initiatives without external capital.
• Valuation uncertainty: Negative EV/EBITDA complicates valuation comparables and may reflect market pricing for distress.
• Earnings recovery risk: With operating income and net income both negative (TTM: -465.70M CNY and -657.46M CNY), return to profitability is required to stabilize leverage metrics.
• Interest rate sensitivity: Elevated debt levels increase exposure to rising funding costs and reduced interest coverage.

Yangmei Chemical Co.,Ltd (600691.SS) - Growth Opportunities

• Product breadth: urea, polyvinyl chloride (PVC), propylene, ion membrane caustic soda, phosphorus trichloride, hydrogen peroxide - serving agriculture and multiple chemical industry value chains.
• Vertical integration: R&D, production and sale of both chemical products and chemical machinery/equipment enhances margin capture and aftermarket service potential.
• Domestic market exposure: Primary operations concentrated in China, aligning with local demand for agricultural inputs (urea) and industrial feedstocks (PVC, propylene).

• Potential growth drivers:
  • Operational leverage from improved utilization or cost control that could explain outsized earnings and EPS growth versus revenue.
  • Product mix shifts toward higher-margin chemical intermediates or equipment sales and services.
  • R&D-driven incremental products or efficiency gains in coal-to-chemicals processes.

• Key investor considerations:
  • High earnings and EPS growth forecasts (111.1% and 110.3% p.a.) suggest either a low base effect or significant one-time/recurring margin improvements-validate with quarterly filings.
  • Relatively low forecast ROE (1.2% in three years) implies capital intensity or retained losses still pressuring equity returns; monitor capital allocation and balance sheet repair.
  • Concentration risk from coal-chemical exposure and China-centric sales - assess regulatory, commodity-price and energy-cost sensitivity.